leflunomide has been researched along with Sclerosis, Systemic in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide." | 7.88 | Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018) |
| "Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide." | 3.88 | Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SY | 1 |
| Lee, SW | 1 |
| Chung, WT | 1 |
| Oliveira, AC | 1 |
| Mota, LM | 1 |
| Santos-Neto, LL | 1 |
| Simões, M | 1 |
| Martins-Filho, OA | 1 |
| Tauil, PL | 1 |
| Gordeev, AV | 1 |
| Mutovina, ZIu | 1 |
| Nasankaeva, EK | 1 |
| Sebastiani, M | 1 |
| Giuggioli, D | 1 |
| Vesprini, E | 1 |
| Caruso, A | 1 |
| Ferri, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area[NCT03430388] | 600 participants (Actual) | Interventional | 2018-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for leflunomide and Sclerosis, Systemic
| Article | Year |
|---|---|
Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report.
Topics: Arthritis, Rheumatoid; Calcinosis; Female; Humans; Immunosuppressive Agents; Leflunomide; Middle Age | 2018 |
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumat | 2015 |
[Effective treatment of systemic sclerosis with leflunomide].
Topics: Aged; Female; Humans; Isoxazoles; Leflunomide; Scleroderma, Systemic; Treatment Outcome | 2005 |
Successful treatment with leflunomide of arthritis in systemic sclerosis patients.
Topics: Adult; Antirheumatic Agents; Arthritis; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; Sclero | 2006 |